vincristine

Group A showed no significant difference in the total efficacy rate and 5-year overall survival after treatment (p > 0.05) and had lower medical expenses, length of hospital stay, IL-6 and TNF-α expression, and total incidence of adverse reactions and higher KPS scores than group B (p < 0.05). Although no significant difference was observed between vindesine and leurocristine in treating pediatric acute lymphoblastic leukemia, patients administered vindesine had fewer adverse reactions, shorter length of hospital stay, lower medical expenses, and higher quality of life than those administered leurocristine, indicating a potential association with decreased serum IL-6 and TNF-α expression.

P2, N=60, Not yet recruiting, Beth Israel Deaconess Medical Center

P1, N=15, Not yet recruiting, National Cancer Institute (NCI)

The patient was started on rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with a good clinical response. Diagnosis was delayed due to the significant procedural barriers as a result of her small stature and microcephaly associated with her Angelman syndrome. Prompt multidisciplinary evaluation and alternative tissue acquisition were essential for diagnosis and treatment.

Here, we investigate the role of IL-1 receptor (IL-1R) signaling in neuropathy induced by vincristine alone and by the standard CVAD regimen (cyclophosphamide, vincristine, doxorubicin, and dexamethasone) in male C57BL6/J mice. IL-1 receptor blockade with the clinically approved antagonist anakinra prevented vincristine-induced mechanical hypersensitivity and attenuated established vincristine-induced peripheral neuropathy, without adverse effects on motor function, hematological parameters, or body weight...Immunohistochemistry and transcriptome profiling of peripheral nervous tissue revealed distinct, time-dependent and agent-specific neuroimmune responses with distinct inflammatory and immunosuppressive effects shaping the net CVAD neuroinflammatory phenotype. Together, these findings redefine chemotherapy-induced peripheral neuropathy as an emergent property of combination chemotherapy and establish IL-1R signaling as a context-dependent therapeutic target with translational relevance.

This study emphasizes the significant association of ABCB1 genotype (TT at rs1045642) with vincristine-associated neuropathy and highlights the relevance of higher average doses of vincristine in causing neurotoxicity.

The patient received eight cycles of alternating VDC/IE (vincristine, doxorubicin, cyclophosphamide / ifosfamide, etoposide) chemotherapy, resulting in a significant reduction in the primary tumor and resolution of the IVC thrombus and skeletal metastases. This case underscores the utility of a multimodal approach, where neoadjuvant chemotherapy can effectively downstage even metastatic disease, facilitating surgical resection. However, the overall prognosis remains poor, particularly for metastatic presentations, highlighting the urgent need for more effective and less toxic therapeutic regimens.

For many years, R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) has been the standard first-line treatment for DLBCL; however, pola-R-CHP (polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone) has recently emerged as a new treatment option...In addition, agents that have demonstrated efficacy in patients with relapsed or refractory DLBCL-such as the anti-CD19 antibody tafasitamab and immunomodulatory drugs such as golcadomide-are currently under investigation for use in newly diagnosed patients...BsAbs can enable more flexible treatment strategies, including combination regimens with cytotoxic or chemotherapy-free approaches. This review summarizes recent advances and ongoing trials that are investigating novel therapeutic strategies for newly diagnosed DLBCL that may soon be incorporated into clinical practice.

P3, N=102, Not yet recruiting, SWOG Cancer Research Network | Initiation date: May 2026 --> Aug 2026

P2, N=32, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China

While rigorous clinical trial data is still emerging, these preliminary cases suggest selumetinib may be a safe and effective therapeutic option for NF1-related OPGs, offering significant tumour control with a favourable toxicity profile compared to chemotherapy. Beyond stabilization, its potential to restore visual function represents a major advance, supporting the potential role of MEK inhibition as a first- and second-line treatment strategy.

P2/3, N=2, Not yet recruiting, Merck Sharp & Dohme LLC